Search
Search Funnelback University
- Refined by:
- Date: Past 6 months
61 -
64 of
64
search results for news |u:mitocamb.medschl.cam.ac.uk
Fully-matching results
-
[11C]PK11195 PET as a biomarker to diagnose and monitor natural…
https://mitocamb.medschl.cam.ac.uk/our-research/research-studies/measuring-studies/11cpk11195-pet-as-a-biomarker-to-diagnose-and-monitor-natural-history-in-mitochondrial-disease/23 Feb 2024: Loading. Menu. Menu. Search. 11C]PK11195 PET as a biomarker to diagnose and monitor natural history in mitochondrial disease. 11C]PK11195 PET as a biomarker to diagnose and monitor natural history in mitochondrial disease. Status: Open to -
Understanding the progression over time of hereditary spastic…
https://mitocamb.medschl.cam.ac.uk/our-research/research-studies/understanding-studies/understanding-the-progression-over-time-of-hereditary-spastic-paraplegia-hsp-ataxia-and-related-conditions-prospax/23 Feb 2024: Loading. Menu. Menu. Search. Understanding the progression over time of hereditary spastic paraplegia (HSP), ataxia and related conditions (PROSPAX). Understanding the progression over time of hereditary spastic paraplegia (HSP), ataxia and related -
DefINe: A randomised, double-blind, placebo-controlled trial…
https://mitocamb.medschl.cam.ac.uk/our-research/clinical-trials/define-a-randomised-double-blind-placebo-controlled-trial-examining-the-safety-and-efficacy-of-deferiprone-in-patients-with-neuroferritinopathy/23 Feb 2024: Loading. Menu. Menu. Search. DefINe: A randomised, double-blind, placebo-controlled trial examining the safety and efficacy of deferiprone in patients with neuroferritinopathy. DefINe: A randomised, double-blind, placebo-controlled trial examining -
OSPREY Study: A Phase I, Open-Label Study to Investigate Antisense…
https://mitocamb.medschl.cam.ac.uk/our-research/clinical-trials/osprey-study-a-phase-i-open-label-study-to-investigate-antisense-oligonucleotide-stk-002-in-patients-with-adoa/23 Feb 2024: Loading. Menu. Menu. Search. OSPREY Study: A Phase I, Open-Label Study to Investigate Antisense Oligonucleotide STK-002 in Patients with ADOA. OSPREY Study: A Phase I, Open-Label Study to Investigate Antisense Oligonucleotide STK-002 in Patients
Refine your results
clear all
Date
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.